MedTrace Logo

A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors

NCT04116710 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2023-08-23

Study results available
· View outcomes & findings →

Summary

This is a phase 1 open-label, single center, dose escalation study to determine a safe and effective maximum tolerated dose of HS-130 in combination with viagenpumatucel-L (HS-110) for adult subjects with advanced solid tumors who are refractory to Standard of Care.

Conditions

  • Advanced Solid Tumor

Interventions

BIOLOGICAL

HS-110 (viagenpumatucel-L)

Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig

BIOLOGICAL

HS-130

Vaccine derived from irradiated human lung cancer cells expressing the co-stimulatory fusion protein OX40L-Ig

Sponsors & Collaborators

  • Heat Biologics

    lead INDUSTRY

Principal Investigators

  • Rachel E. Sanborn, MD · Providence Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-18
Primary Completion
2021-08-12
Completion
2022-04-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04116710 on ClinicalTrials.gov